The MarketWatch News Department was not involved in the creation of this content. BETHESDA, Md., April 17, 2026 /PRNewswire/ -- Precision Biologics, Inc. announces a new target in Acute Myeloid ...
Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...
Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies ...
He also reviews the development of menin inhibitors in AML, including recent regulatory advances in the relapsed/refractory ...
In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to ...
Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML). This is an ASCO ...
The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor ...
BETHESDA, Md., April 17, 2026 /PRNewswire/ -- Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results